TriNetX Oncology GmbH Library - Publications, papers

TriNetX Oncology GmbH Library

Colorectal

Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland

Did the uptake of new treatment options change the treatment strategy in patients with colorectal cancer and primary non-resectable metastases?

The results of large population-based survey in Germany 2005-2007

Esophagogastric

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Population-Based Patterns of Care in the 1st Line Treatment of Patients with Advanced Esophagogastric Adenocarcinoma in Germany

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Trastuzumab in Esophagogastric Cancer

HER2-Testing and Treatment Reality outside Clinical Studies in Germany

Gastric

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Population-based patterns of care in the treatment of 678 patients with gastric cancer

Lung

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Disparities in Access to EGFR‐Mutation Testing in Patients with Advanced NSCLC in Germany 2011

Lymphoma/Leukemia

Behandlung indolenter Lymphome in Deutschland

Ergebnisse einer repräsentativen nationalen Erhebung

Treatment of Chronic Lymphocytic Leukemia in Germany Results of a representative population‐based survey in 2011

Treatment of Chronic Lymphocytic Leukemia in Germany Results of a representative population‐based survey in 2011

Treatment of Chronic Lymphocytic Leukemia in Germany Results of a representative population‐based survey in 2011

Indolente Non Hodgkin Lymphome

Trends in der Diagnose und in der Therapie in Deutschland (2006-2009)

MDS

Erste Ergebnisse einer multizentrischen retrospektiven Analyse zur Diagnose und Behandlung von MDS-Patienten in Deutschland

Real-world data in a German healthcare survey demonstrate a high medical need of patients with lower risk MDS and ringsideroblasts

Multiple Myeloma

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey. Session Type: Publication Only

Treatment Situation for Newly Diagnosed Multiple Myeloma Patients in Germany

First Results from a Representative Multicentre Treatment Survey

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Role of Bortezomib in the Treatment of Multiple Myeloma

First Results from a Representative Multicentre Treatment Survey in Germany

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey. Session Type: Publication Only

Anwendung neuer Therapien zur Behandlung des multiplen Myeloms

Ergebnisse einer repräsentativen multizentrischen Erhebung 2006

How to treat multiple myeloma – a representative multicentre treatment survey

How to treat multiple myeloma – a representative multicentre treatment survey

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Treatment of multiple myeloma in Germany

An update of a representative multicentre health care survey 2004‐2011

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey. Session Type: Publication Only

Diagnostic and therapeutic approaches to multiple myeloma patients

‘Real-world’ data from representative multicentre treatment surveys in Germany between 2008 and 2011

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Diagnosis and treatment of multiple myeloma in Germany

Analysis of a nationwide, multi-institutional survey

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma in Europe from 2016 to 2018

Analysis of a Multi-National Survey

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Baseline characteristics and survival outcomes of patients with tri-exposed multiple myeloma in a German registry

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD-38 from a German registry

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Treatment Patterns in Patients with Refractory/Relapsed Multiple Myeloma in Germany Between 2016 and 2018

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Comparative Effectiveness of Pomalidomide Plus Low-Dose Dexamethasone (POM+LoDEX) in Relapsed and Refractory Multiple Myeloma

Use of Real-World Data in the Absence of Head-to-Head Studies

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

Real-world patient characteristics and survival outcomes of lenalidomide-refractory vs. lenalidomide-exposed RRMM patients in the HONEUR federated data network

Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry

The Impact of the SARS-CoV-2 Pandemic (COVID-19) on the Incidence of Newly Diagnosed Multiple Myeloma Patients Using a Federated Network of Real-World Evidence in US and Germany

Ovarian

Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland

Prostate

SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC) in Germany

Download a sample hematological TherapyMonitor Report

TriNetX Oncology GmbH is your trusted source for TherapyMonitor – comprehensive analyses revealing current disease prevalence, treatment patterns, and indication-specific market dynamics based on longitudinal, patient-level data.

Learn more about TriNetX Oncology GmbH

Join the expedition to a range of EU oncology care

TriNetX Oncology GmbH is a wholly owned subsidiary of TriNetX, LLC.